Kortikosteroidkatarakte nach Nierentransplantation

Koch, H.-R.; Weikenmeier, Peter; Siedek, M

doi:10.1007/bf00408274

Cited by 9 publications

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Eye toxicity of cancer chemotherapy: A review of the literature

Griffin

Garnick

1981

Cancer

View full text Add to dashboard Cite

Eye toxicity from cancer chemotherapy is uncommon, but important because of the debility caused by loss of vision. The literature describing eye toxicity is reviewed for commonly used antineoplastic agents.Cancer 48:1539-1549, 1981. HE UTILITY OF ANTINEOPLASTIC AGENTS is fre-T quently limited by toxic side effects such as prolonged myelosuppression, peripheral neuropathy , nausea, and vomiting. Ocular toxicity, though uncommon, may be very disabling. This report discusses the clinical manifestations and pathophysiology of the ocular side effects associated with commonly used antineoplastic agents. The toxic effects of combining systemic cancer chemotherapy with radiotherapy or intrathecal therapy is also reviewed. Chemotherapeutic Agents Busulfan and DibromomannitolBusulfan (Myleran) is an alkylating agent used in the treatment of chronic myelogenous leukemia (CML). It commonly produces bone marrow suppression, and long-term use may lead to pulmonary f i b r o s i~.~~~~~~ In preclinical toxicology studies, rats given busulfan, 12.5 mglkg, developed reduced mitotic activity in the lens epithelium and nuclear disintigration with chromatin a g g r e g a t i~n .~~ When rats were fed busulfan daily at 1-2.5 mg/kg/day, anterior and posterior subcapsular cataracts developed after 4-5 weeks. In similar studies with dibromomannitol, an agent also useful in treating CML, chronic feeding of the drug to rats produced posterior subcapsular cataracts (PSC).I2OIn a clinical study, 45 patients with chronic myelog-

show abstract